Suzetrigine · Journavx

Small molecule

Also known as VX-548

Approvedregulatory verdict

Evidence outlook

Approved: Acute Pain

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Diabetic Peripheral Neuropathic Pain · Phase 3

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (14)
Acute Pain
NCT05661734 · Vertex Pharmaceuticals Incorporated
2023-01-09 – 2023-12-12 · Pain
What this study did
Diabetic Peripheral Neuropathic Pain
NCT06696443 · Vertex Pharmaceuticals Incorporated
2024-12-18 – 2027-01-25 · Diabetic Peripheral Neuropathic Pain
What this study did
Other / comorbidity
NCT07864896 · Hospital for Special Surgery, New York
2026-10-15 – 2030-01 · Total Knee Arthroplasty (TKA), Total Knee Arthroplasty \(TKA\), Total Knee Replacement, Total Knee Replacement Surgery, Total Knee Replacements, Total Knee Replacement Arthroplasty, Suzetrigine, Pain Management, Pain, Nav 1.8, JOURNAVX, Opioid Cessation, Opioid Consumption, Postoperative, Multimodal Analgesia, Randomized Controlled Trial, Randomized Controlled Study, Randomized Controlled Trials
What this study did
NCT07226700 · Hospital for Special Surgery, New York
2025-11-03 – 2028-11-01 · Total Hip Arthroplasty (THA), Total Hip Arthroplasty \(THA\), Total Hip Replacement, Total Hip Replacement Surgery, Total Hip Replacements, Total Hip Replacement Arthroplasty, Suzetrigine, Pain Management, Pain, Nav 1.8, JOURNAVX, Opioid Cessation, Opioid Consumption, Postoperative, Multimodal Analgesia, Randomized Controlled Trial, Randomized Controlled Study, Randomized Controlled Trials
What this study did
Suzetrigine Post DIEPnot yet recruiting
NCT07839715 · Vanderbilt University Medical Center
2026-09 – 2027-08 · Post-operative Pain, DIEP Flap Breast Reconstruction, DIEP Flap, Opioid, Suzetrigine, ERAS
What this study did
NCT07525219 · Wake Forest University Health Sciences
2026-06-22 – 2027-07 · Analgesic Efficacy
What this study did
NCT07654296 · Brigham and Women's Hospital
2026-10-20 – 2027-05-31 · Opioid Consumption, Postoperative, Multimodal Analgesia, Ureteroscopy, Ureteral Stents, Ureteral Stent-Related Symptoms
What this study did
NCT07548385 · Icahn School of Medicine at Mount Sinai
2026-04 – 2027-02-23 · Total Knee Replacement Surgery, Post-operative Pain
What this study did
NCT07539623 · Icahn School of Medicine at Mount Sinai
2026-05-01 – 2026-12-22 · Bariatric Surgery, Cardiac Surgery With Sternotomy, Post-operative Pain
What this study did
NCT07357376 · AdventHealth
2026-03-01 – 2026-08-01 · Postoperative Pain Following Knee Arthroplasty
What this study did
Phase 2 (4)
Acute Pain
NCT04977336 · Vertex Pharmaceuticals Incorporated
2021-07-19 – 2022-03-04 · Acute Pain
What this study did
NCT05034952 · Vertex Pharmaceuticals Incorporated
2021-08-30 – 2021-12-21 · Acute Pain
What this study did
Diabetic Peripheral Neuropathic Pain
Other / comorbidity
NCT06176196 · Vertex Pharmaceuticals Incorporated
2023-12-13 – 2024-10-16 · Painful Lumbosacral Radiculopathy
What this study did
Phase 1 (15)
Acute Pain
NCT07511400 · Medical University of Vienna
2026-04-21 – 2026-06-09 · Pain, Acute Pain, Healthy Volunteer Study
What this study did
Other / comorbidity
NCT07378865 · Vertex Pharmaceuticals Incorporated
2026-02-13 – 2026-08-17 · Pain
What this study did
NCT07570069 · Vertex Pharmaceuticals Incorporated
2026-05-07 – 2026-07-16 · Pain
What this study did
NCT06972212 · Latigo Biotherapeutics
2025-06-04 – 2025-06-28 · Pain Detection, Pain Threshold
What this study did
NCT06820307 · Vertex Pharmaceuticals Incorporated
2025-02-25 – 2025-04-29 · Pain
What this study did
NCT06834009 · Vertex Pharmaceuticals Incorporated
2025-03-10 – 2025-04-24 · Pain
What this study did
NCT06420765 · Vertex Pharmaceuticals Incorporated
2024-05-21 – 2025-04-04 · Pain
What this study did
NCT06336096 · Vertex Pharmaceuticals Incorporated
2024-03-28 – 2024-06-19 · Pain
What this study did
NCT05704556 · Vertex Pharmaceuticals Incorporated
2023-02-27 – 2024-03-30 · Pain
What this study did
NCT05851157 · Vertex Pharmaceuticals Incorporated
2023-05-03 – 2023-11-08 · Pain
What this study did
NCT05560464 · Vertex Pharmaceuticals Incorporated
2022-10-14 – 2023-07-24 · Pain
What this study did
NCT05818852 · Vertex Pharmaceuticals Incorporated
2023-04-12 – 2023-06-28 · Pain
What this study did
NCT05635110 · Vertex Pharmaceuticals Incorporated
2022-12-15 – 2023-06-08 · Pain
What this study did
NCT05541471 · Vertex Pharmaceuticals Incorporated
2022-09-22 – 2023-04-28 · Pain
What this study did
NCT05455502 · Vertex Pharmaceuticals Incorporated
2022-07-13 – 2022-09-17 · Pain
What this study did
Phase 4 (25)
Acute Pain
NCT07843134 · University of Minnesota
2027-04-01 – 2029-07-30 · Postoperative Pain, Acute Pain, Skin Cancer, Cutaneous Malignancy, Mohs Surgery
What this study did
NCT07795827 · Soheil Ashkani Esfahani
2026-10-01 – 2028-04-01 · Ankle Osteoarthritis, Postoperative Pain, Acute Pain
What this study did
NCT07145346 · University of California, Irvine
2025-11-13 – 2027-08 · Rib Fractures
What this study did
NCT07821931 · Stanford University
2026-11 – 2027-07 · Tonsillectomy, Pharyngoplasty, Suzetrigine, Opioid, Postoperative Pain, Acute Pain
What this study did
NCT06887959 · Vertex Pharmaceuticals Incorporated
2025-03-27 – 2025-11-10 · Acute Pain
What this study did
NCT06887972 · Vertex Pharmaceuticals Incorporated
2025-03-21 – 2025-11-07 · Acute Pain
What this study did
Other / comorbidity
NCT07829718 · Ohio State University
2026-09-13 – 2030-12-30 · Spine Fusion, Postoperative Pain
What this study did
NCT07820969 · University of Miami
2026-10-01 – 2028-10-01 · Nail Diseases
What this study did
NCT07866638 · University of Alabama at Birmingham
2026-11-01 – 2028-09-01 · Artroscopic Surgery, Pain Management, Pain After Shoulder Surgery, Opioid Consumption, Opioid Consumption, Postoperative
What this study did
NCT07624526 · Emory University
2026-07 – 2028-08 · Knee Arthritis, Knee Osteoarthritis
What this study did
NCT07905404 · Beth Israel Deaconess Medical Center
2027-01-05 – 2028-07-30 · Hip Fractures (ICD-10 72.01-72.2), Post Operative Analgesia
What this study did
NCT07600697 · University of California, Los Angeles
2026-11-01 – 2028-07-01 · Pelvic Organ Prolapse (POP), Stress Urinary Incontinence (SUI), Postoperative Pain
What this study did
NCT07534709 · University of Texas at Austin
2026-06 – 2028-05 · Cesarean Delivery, Cesarean Section, Pain, Postoperative, Opioid Consumption, Postoperative
What this study did
NCT07856654 · Aditi Talkad
2026-11 – 2028-05 · Pelvic Organ Prolapse (POP), Postoperative Pain, Urogynecology
What this study did
NCT07836010 · Duke University
2026-11 – 2028-02 · Postoperative Pain
What this study did
NCT07796152 · Endeavor Health
2026-09 – 2028-01 · Knee Arthroplasty, Total, Post Operative Pain, Acute, Opioid Consumption, Postoperative
What this study did
NCT07575230 · Baylor Research Institute
2025-11-03 – 2027-12 · Cutaneous Tumors, Mohs Micrographic Surgery
What this study did
NCT07463430 · University of California, San Diego
2026-04-14 – 2027-06-30 · Pain, Acute Postoperative, Breast Disease
What this study did
NCT07672015 · University of California, San Diego
2026-07-02 – 2027-06 · Opioid Consumption, Postoperative
What this study did
NCT07219888 · University of Louisville
2026-02-09 – 2027-04-30 · Osteoarthritis (OA) of the Knee
What this study did
NCT07928011 · University of California, Irvine
2027-01 – 2027-04 · Total Knee Arthroplasty
What this study did
NCT07355166 · University of California, Los Angeles
2026-09 – 2027-03 · Postoperative Pain Management
What this study did
NCT07538570 · Vertex Pharmaceuticals Incorporated
2026-04-24 – 2026-10-22 · Pain
What this study did
NCT07257133 · Mayo Clinic
2025-10-20 – 2026-04-01 · Post Operative Pain
What this study did
NCT07195669 · Jacob Lensing
2025-10-01 – 2026-01-30 · Pain Control
What this study did
Used as active comparator (2)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 2 (1)
Acute Pain
NCT06774625 · Latigo Biotherapeutics
2024-12-19 – 2025-08-08 · Acute Pain, Postoperative
What this study did
Phase 4 (1)
Other / comorbidity
NCT07938840 · OrthoCarolina Research Institute, Inc.
2026-12-01 – 2028-12-31 · Osteo Arthritis Shoulders, Avascular Necrosis of Bone
What this study did

Competitive landscape

Other Voltage-gated sodium channel NaV1.8 drugs

JMKX000623, VX-993. Compare all 3 Voltage-gated sodium channel NaV1.8 drugs

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Acute Pain: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Suzetrigine (Journavx): this drugApprovedSmall moleculeVoltage-gated sodium channel NaV1.8Reliable signal
NCT05553366: Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48), SUZ Compared to Placebo (0 to 48 hours After First Dose of Study Drug): Placebo 70.6 units on a scale (Standard Error 6.3) | Suzetrigine (SUZ) 99.9 units on a scale (Standard Error 4.5)
NCT05558410: Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48) SUZ Compared to Placebo (0 to 48 hours After First Dose of Study Drug): Placebo 70.1 units on a scale (Standard Error 6.1) | Suzetrigine (SUZ) 118.4 units on a scale (Standard Error 4.3)
Bupivacaine Liposome (Exparel)ApprovedSmall moleculeAmide Local Anestheticnot yet gradedNo reviewed efficacy summary in this indication
HRS-2129
Phase 1(overall)
Small molecule—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(30 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Journavx (Suzetrigine) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 3Bariatric Surgery, Cardiac Surgery With Sternotomy, Post-operative PainRecruiting
Est. primary completion 2026-12-22 · NCT07539623 · CT.gov ↗
What to watch
Phase 4Osteoarthritis (OA) of the KneeEnrolling by invitation
Est. primary completion 2026-12-31 · NCT07219888 · CT.gov ↗
What to watch
2027 (19)
January 2027 (2)
Phase 4Postoperative Pain ManagementNot yet recruiting
Est. primary completion 2027-01 · NCT07355166 · CT.gov ↗
What to watch
Phase 3Diabetic Peripheral Neuropathic PainActive not recruiting
Est. primary completion 2027-01-25 · NCT06696443 · CT.gov ↗
What to watch
February 2027 (1)
Phase 3Total Knee Replacement Surgery, Post-operative PainRecruiting
Est. primary completion 2027-02-23 · NCT07548385 · CT.gov ↗
What to watch
March 2027 (2)
Phase 4Total Knee ArthroplastyNot yet recruiting
Est. primary completion 2027-03 · NCT07928011 · CT.gov ↗
What to watch
Phase 3Opioid Consumption, Postoperative, Multimodal Analgesia, Ureteroscopy, Ureteral Stents, Ureteral Stent-Related SymptomsRecruiting
Est. primary completion 2027-03-31 · NCT07654296 · CT.gov ↗
What to watch
April 2027 (1)
Phase 3Diabetic Peripheral Neuropathic PainRecruiting
Est. primary completion 2027-04-06 · NCT07231419 · CT.gov ↗
What to watch
May 2027 (1)
Phase 3Diabetic Peripheral Neuropathic PainRecruiting
Est. primary completion 2027-05-31 · NCT06628908 · CT.gov ↗
What to watch
June 2027 (3)
Phase 4Opioid Consumption, PostoperativeRecruiting
Est. primary completion 2027-06 · NCT07672015 · CT.gov ↗
What to watch
Phase 4Acute PainNot yet recruiting
Est. primary completion 2027-06 · NCT07821931 · CT.gov ↗
What to watch
Phase 4Pain, Acute Postoperative, Breast DiseaseEnrolling by invitation
Est. primary completion 2027-06-27 · NCT07463430 · CT.gov ↗
What to watch
July 2027 (2)
Phase 3Analgesic EfficacyRecruiting
Est. primary completion 2027-07 · NCT07525219 · CT.gov ↗
What to watch
Phase 4Pelvic Organ Prolapse (POP), Stress Urinary Incontinence (SUI), Postoperative PainNot yet recruiting
Est. primary completion 2027-07-01 · NCT07600697 · CT.gov ↗
What to watch
August 2027 (2)
Phase 3Post-operative Pain, DIEP Flap Breast Reconstruction, DIEP Flap, Opioid, Suzetrigine, ERASNot yet recruiting
Est. primary completion 2027-08 · NCT07839715 · CT.gov ↗
What to watch
Phase 4Acute PainEnrolling by invitation
Est. primary completion 2027-08 · NCT07145346 · CT.gov ↗
What to watch
October 2027 (1)
Phase 4Acute PainNot yet recruiting
Est. primary completion 2027-10-01 · NCT07795827 · CT.gov ↗
What to watch
November 2027 (1)
Phase 3Total Hip Arthroplasty (THA), Total Hip Arthroplasty \(THA\), Total Hip Replacement, Total Hip Replacement Surgery, Total Hip Replacements …Recruiting
Est. primary completion 2027-11-01 · NCT07226700 · CT.gov ↗
What to watch
December 2027 (3)
Phase 4Cutaneous Tumors, Mohs Micrographic SurgeryEnrolling by invitation
Est. primary completion 2027-12 · NCT07575230 · CT.gov ↗
What to watch
Phase 4Knee Arthroplasty, Total, Post Operative Pain, Acute, Opioid Consumption, PostoperativeNot yet recruiting
Est. primary completion 2027-12 · NCT07796152 · CT.gov ↗
What to watch
Phase 4Pelvic Organ Prolapse (POP), Postoperative Pain, UrogynecologyNot yet recruiting
Est. primary completion 2027-12 · NCT07856654 · CT.gov ↗
What to watch
2028 (6)
January 2028 (1)
Phase 4Postoperative PainNot yet recruiting
Est. primary completion 2028-01 · NCT07836010 · CT.gov ↗
What to watch
February 2028 (1)
Phase 4Cesarean Delivery, Cesarean Section, Pain, Postoperative, Opioid Consumption, PostoperativeNot yet recruiting
Est. primary completion 2028-02 · NCT07534709 · CT.gov ↗
What to watch
July 2028 (1)
Phase 4Hip Fractures (ICD-10 72.01-72.2), Post Operative AnalgesiaNot yet recruiting
Est. primary completion 2028-07-30 · NCT07905404 · CT.gov ↗
What to watch
August 2028 (1)
Phase 4Knee Arthritis, Knee OsteoarthritisNot yet recruiting
Est. primary completion 2028-08 · NCT07624526 · CT.gov ↗
What to watch
September 2028 (1)
Phase 4Artroscopic Surgery, Pain Management, Pain After Shoulder Surgery, Opioid Consumption, Opioid Consumption, PostoperativeNot yet recruiting
Est. primary completion 2028-09-01 · NCT07866638 · CT.gov ↗
What to watch
October 2028 (1)
Phase 4Nail DiseasesNot yet recruiting
Est. primary completion 2028-10-01 · NCT07820969 · CT.gov ↗
What to watch
2029 (2)
January 2029 (1)
Phase 3Total Knee Arthroplasty (TKA), Total Knee Arthroplasty \(TKA\), Total Knee Replacement, Total Knee Replacement Surgery …Recruiting
Est. primary completion 2029-01 · NCT07864896 · CT.gov ↗
What to watch
April 2029 (1)
Phase 4Acute PainNot yet recruiting
Est. primary completion 2029-04-30 · NCT07843134 · CT.gov ↗
What to watch
2030 (1)
December 2030 (1)
Phase 4Spine Fusion, Postoperative PainNot yet recruiting
Est. primary completion 2030-12-30 · NCT07829718 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(4)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

30 January 2025FDA action datePDUFA target date set
US, FDA · Source ↗
30 July 2024Filing acceptedFDA accepts suzetrigine NDA
US, FDA · Source ↗
30 July 2024Priority reviewFDA grants priority review
US, FDA · Source ↗
January 2024Topline resultVX-548 bunionectomy Phase 3 (NCT05553366) met its primary endpoint
Vertex Pharmaceuticals Incorporated · Source ↗